Abstract | BACKGROUND: METHODS: Patients in sequential cohorts (3 + 3 design) received intravenous EZN-2208 at doses between 1.25 mg/m(2) and 25 mg/m(2) once every 21 days. RESULTS: CONCLUSIONS:
EZN-2208 was well tolerated and produced stable disease that lasted for ≥ 4 months/unconfirmed partial responses in 7 of 39 heavily pretreated patients (18%) with advanced solid tumors, including those who had failed prior irinotecan therapy.
|
Authors | Razelle Kurzrock, Sanjay Goel, Jennifer Wheler, David Hong, Siqing Fu, Keyvan Rezai, Sonia K Morgan-Linnell, Saik Urien, Sridhar Mani, Imran Chaudhary, Mohammed H Ghalib, Aby Buchbinder, François Lokiec, Mary Mulcahy |
Journal | Cancer
(Cancer)
Vol. 118
Issue 24
Pg. 6144-51
(Dec 15 2012)
ISSN: 1097-0142 [Electronic] United States |
PMID | 22674635
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 American Cancer Society. |
Chemical References |
- DNA, Neoplasm
- EZN-2208
- Polyethylene Glycols
- UGT1A1 enzyme
- Glucuronosyltransferase
- Camptothecin
|
Topics |
- Adult
- Aged
- Camptothecin
(analogs & derivatives, pharmacokinetics, therapeutic use)
- DNA, Neoplasm
(genetics)
- Female
- Follow-Up Studies
- Glucuronosyltransferase
(blood, genetics)
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Neoplasms
(drug therapy, genetics)
- Polyethylene Glycols
(pharmacokinetics, therapeutic use)
- Polymerase Chain Reaction
- Polymorphism, Genetic
(genetics)
- Prognosis
- Safety
- Tissue Distribution
|